CRISP3 expression drives prostate cancer invasion and progression.


Journal

Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481

Informations de publication

Date de publication:
07 2020
Historique:
received: 28 04 2020
accepted: 01 05 2020
pubmed: 2 5 2020
medline: 29 9 2021
entrez: 2 5 2020
Statut: ppublish

Résumé

Identifying the factors stimulating prostate cancer cells migration and invasion has the potential to bring new therapeutic targets to the clinic. Cysteine-rich secretory protein 3 (CRISP3) is one of the most highly upregulated proteins during the transition of a healthy human prostatic epithelium to prostate cancer. Here we show using a genetically engineered mouse model of prostate cancer that CRISP3 production greatly facilitates disease progression from carcinoma in situ to invasive prostate cancer in vivo. This interpretation was confirmed using both human and mouse prostate cancer cell lines, which showed that exposure to CRISP3 enhanced cell motility and invasion. Further, using mass spectrometry, we show that CRISP3 induces changes in abundance of a subset of cell-cell adhesion proteins, including LASP1 and TJP1 both in vivo and in vitro. Collectively, these data identify CRISP3 as being pro-tumorigenic in the prostate and validate it as a potential target for therapeutic intervention.

Identifiants

pubmed: 32357309
doi: 10.1530/ERC-20-0092
pii: ERC-20-0092
doi:
pii:

Substances chimiques

CRISP3 protein, human 0
Salivary Proteins and Peptides 0
Seminal Plasma Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

415-430

Auteurs

Marianna Volpert (M)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.

Luc Furic (L)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Jinghua Hu (J)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia.

Anne E O'Connor (AE)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia.

Richard J Rebello (RJ)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.

Shivakumar Keerthikumar (S)

Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Computational Cancer Biology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Jemma Evans (J)

The Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Department of Physiology, Monash University, Clayton, Victoria, Australia.

D Jo Merriner (DJ)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia.

John Pedersen (J)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.

Gail P Risbridger (GP)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
Prostate Cancer Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

Peter McIntyre (P)

Health Innovations Research Institute and School of Medical Sciences, RMIT University, Bundoora, Victoria, Australia.

Moira K O'Bryan (MK)

Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia.
The School of Biological Sciences, Monash University, Clayton, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH